Expert Opinion on Biological Therapy最新文献

筛选
英文 中文
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target. IL-23 在银屑病关节炎中的免疫学作用:潜在的治疗靶点。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1080/14712598.2024.2401148
Qin-Yi Su, Heng-Yan Gao, Yue-Ru Duan, Jing Luo, Wei-Ze Wang, Xi-Chao Qiao, Sheng-Xiao Zhang
{"title":"The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target.","authors":"Qin-Yi Su, Heng-Yan Gao, Yue-Ru Duan, Jing Luo, Wei-Ze Wang, Xi-Chao Qiao, Sheng-Xiao Zhang","doi":"10.1080/14712598.2024.2401148","DOIUrl":"10.1080/14712598.2024.2401148","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriatic arthritis (PsA) is a debilitating chronic condition characterized by inflammation of the joints, bones, enthesis, and skin. The pivotal role of interleukin-23 (IL-23) in the pathogenesis of PsA has become increasingly evident. This proinflammatory cytokine is markedly elevated in patients with PsA, suggesting its potential as a therapeutic target. Consequently, IL-23 inhibitors have emerged as promising first-line biologic treatments for PsA.</p><p><strong>Areas covered: </strong>This review delves into the immunopathogenic mechanisms of IL-23 at the cellular and molecular levels in PsA. Furthermore, it provides the recent efficacy and safety profiles of IL-23 inhibitors. We conducted a literature search in PubMed for the following terms: 'IL-23 and psoriatic arthritis,' 'Ustekinumab,' 'Guselkumab,' 'Risankizumab,' and 'Tildrakizumab.' In addition, we retrieved clinical trials involving IL-23 inhibitors registered in ClinicalTrials.gov, EudraCT, and ICTRP.</p><p><strong>Expert opinion: </strong>Despite the promising outcomes observed with IL-23 inhibitors, several challenges persist. The long-term effects of these agents require further investigation through prospective studies, and their limited accessibility worldwide necessitates urgent attention. Additionally, ongoing research is warranted to explore other potential drug targets within the IL-23/IL-23 R axis. The development of reliable biomarkers could greatly enhance early detection, tailored management strategies, and personalized treatment approaches for patients with PsA.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Probiotic therapy as a promising strategy for gestational diabetes mellitus management. 益生菌疗法是治疗妊娠糖尿病的有效策略。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-30 DOI: 10.1080/14712598.2024.2409880
Deborah Emanuelle de Albuquerque Lemos, José Luiz de Brito Alves, Evandro Leite de Souza
{"title":"Probiotic therapy as a promising strategy for gestational diabetes mellitus management.","authors":"Deborah Emanuelle de Albuquerque Lemos, José Luiz de Brito Alves, Evandro Leite de Souza","doi":"10.1080/14712598.2024.2409880","DOIUrl":"https://doi.org/10.1080/14712598.2024.2409880","url":null,"abstract":"<p><strong>Introduction: </strong>Gestational diabetes mellitus (GDM) has become the most common pregnancy medical complication, and its prevalence has increased in recent years. The GDM treatment primarily relies on adopting healthy eating habits, physical exercise, and insulin therapy. However, using probiotics to modulate the gut microbiota has been the subject of clinical trials as a promising therapeutic strategy for GDM management.</p><p><strong>Areas covered: </strong>Due to the adverse effects of gut dysbiosis in women with GDM, strategies targeting the gut microbiota to mitigate hyperglycemia, low-grade inflammation, and adverse pregnancy outcomes have been explored. Probiotic supplementation may improve glucose metabolism, lipid profile, oxidative stress, inflammation, and blood pressure in women with GDM. Furthermore, decreased fasting blood glucose, insulin resistance, and inflammatory markers, such as TNF-α and CRP, as well as increased total antioxidant capacity, lipid profile modulation, and improved blood pressure in women with GDM, are some of the important results reported in the available literature.</p><p><strong>Expert opinion: </strong>To fill the knowledge gap, further studies are needed focusing on modulating gut microbiota composition and metabolic activity and their systemic repercussions in GDM.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent developments in CD19-targeted therapies for follicular lymphoma. CD19靶向治疗滤泡性淋巴瘤的最新进展。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-18 DOI: 10.1080/14712598.2024.2404100
Aditi Saha,Julio C Chavez
{"title":"Recent developments in CD19-targeted therapies for follicular lymphoma.","authors":"Aditi Saha,Julio C Chavez","doi":"10.1080/14712598.2024.2404100","DOIUrl":"https://doi.org/10.1080/14712598.2024.2404100","url":null,"abstract":"INTRODUCTIONCD19 has emerged as an important and novel therapeutic target in follicular lymphoma. CD19-directed therapies, including monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, offer promising avenues for treating follicular lymphoma and improving outcomes.AREAS COVEREDWe review the role and rationale of targeting CD19 in follicular lymphoma and different interventions of CD19 targeting, such as cell therapy, bispecific antibodies, antibody-drug conjugates, and monoclonal antibodies. We finalize with a discussion on how these therapies may influence the treatment landscape of follicular lymphoma.EXPERT OPINIONCD19 is an attractive target for therapeutic development in follicular lymphoma. Given its effectiveness, it will continue to move forward as a promising therapy for this disease.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142266209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of interleukin gene therapy in head and neck cancers. 白细胞介素基因疗法在头颈部癌症中的前景。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-18 DOI: 10.1080/14712598.2024.2405568
Cosima C Hoch,Khouloud Hachani,Yu Han,Benedikt Schmidl,Markus Wirth,Gabriele Multhoff,Ali Bashiri Dezfouli,Barbara Wollenberg
{"title":"The future of interleukin gene therapy in head and neck cancers.","authors":"Cosima C Hoch,Khouloud Hachani,Yu Han,Benedikt Schmidl,Markus Wirth,Gabriele Multhoff,Ali Bashiri Dezfouli,Barbara Wollenberg","doi":"10.1080/14712598.2024.2405568","DOIUrl":"https://doi.org/10.1080/14712598.2024.2405568","url":null,"abstract":"INTRODUCTIONHead and neck cancer (HNC), primarily head and neck squamous cell carcinomas, originates from the squamous epithelium in areas like the oral cavity, lip, larynx, and oropharynx. With high morbidity impacting critical functions, combined treatments like surgery, radiation, and chemotherapy often fall short in advanced stages, highlighting the need for innovative therapies.AREAS COVEREDThis review critically evaluates interleukin (IL) gene therapy for treating HNC. The discussion extends to key ILs in HNC, various gene therapy techniques and delivery methods. We particularly focus on the application of IL-2, IL-12, and IL-24 gene therapies, examining their mechanisms and outcomes in preclinical studies and clinical trials. The final sections address IL gene therapy challenges in HNC, exploring solutions and critically assessing future therapeutic directions.EXPERT OPINIONDespite advancements in genomic and immunotherapy, significant challenges in HNC treatment persist, primarily due to the immunosuppressive nature of the tumor microenvironment and the adverse effects of current therapies. The therapeutic efficacy of IL gene therapy hinges on overcoming these hurdles through refined delivery methods that ensure targeted, tumor-specific gene expression. Future strategies should focus on refining gene delivery methods and combining IL gene therapy with other treatments to optimize efficacy and minimize toxicity.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142266214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars 非小细胞肺癌患者的长期无进展生存期:聚焦贝伐珠单抗及其生物仿制药
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-16 DOI: 10.1080/14712598.2024.2405562
Fran Seiwerth, Lela Bitar, Miroslav Samaržija, Marko Jakopović
{"title":"Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars","authors":"Fran Seiwerth, Lela Bitar, Miroslav Samaržija, Marko Jakopović","doi":"10.1080/14712598.2024.2405562","DOIUrl":"https://doi.org/10.1080/14712598.2024.2405562","url":null,"abstract":"In the era of immunotherapy, bevacizumab seems to be losing its place in NSCLC treatment algorithms. The aim of this work is to try to define the advantages and disadvantages of NSCLC treatment wit...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142266210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness 在克罗恩病中使用生物仿制药的临床经验及其有效性
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-13 DOI: 10.1080/14712598.2024.2401616
Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet
{"title":"Clinical experience of using biosimilars in Crohn’s disease and their effectiveness","authors":"Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet","doi":"10.1080/14712598.2024.2401616","DOIUrl":"https://doi.org/10.1080/14712598.2024.2401616","url":null,"abstract":"The approval of biosimilars in the management of inflammatory bowel diseases (IBDs) has offered an answer to a growing concern about healthcare costs, and availability of treatments. Several studie...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142183434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis 老年类风湿关节炎患者使用生物疗法的注意事项
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-13 DOI: 10.1080/14712598.2024.2404521
Noor Nooh, May N Lwin, Christopher Edwards
{"title":"Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis","authors":"Noor Nooh, May N Lwin, Christopher Edwards","doi":"10.1080/14712598.2024.2404521","DOIUrl":"https://doi.org/10.1080/14712598.2024.2404521","url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that primarily affects middle-aged individuals but is increasingly prevalent among the elderly due to longer life expectancies...","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142183435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mosunetuzumab for the treatment of follicular lymphoma. 用于治疗滤泡性淋巴瘤的莫苏尼珠单抗。
IF 4.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-11 DOI: 10.1080/14712598.2024.2404079
Caterina Labanca,Enrica Antonia Martino,Ernesto Vigna,Antonella Bruzzese,Francesco Mendicino,Paola De Luca,Eugenio Lucia,Virginia Olivito,Valentina Fragliasso,Antonino Neri,Fortunato Morabito,Massimo Gentile
{"title":"Mosunetuzumab for the treatment of follicular lymphoma.","authors":"Caterina Labanca,Enrica Antonia Martino,Ernesto Vigna,Antonella Bruzzese,Francesco Mendicino,Paola De Luca,Eugenio Lucia,Virginia Olivito,Valentina Fragliasso,Antonino Neri,Fortunato Morabito,Massimo Gentile","doi":"10.1080/14712598.2024.2404079","DOIUrl":"https://doi.org/10.1080/14712598.2024.2404079","url":null,"abstract":"INTRODUCTIONFollicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history, and a median survival of approximately 18-20 years. The advent of anti-CD20 monoclonal antibodies has changed the FL therapeutic algorithm, with an increase in progression-free survival. T-cell-dependent bispecific antibodies (BsAbs) represent an emerging drug class against FL.AREAS COVEREDIn this review, we selected papers from the principal databases (PubMed, Medline, Medscape, ASCO, ESMO) between January 2021 and June 2024, using the keywords 'mosunetuzumab' and 'follicular lymphoma' to provide an overview of mosunetuzumab-axgb, a pioneering BsAb. Its mechanism of action, efficacy, safety and future perspectives were analyzed.EXPERT OPINIONmosunetuzumab grants a directing T-cell mediated cytotoxicity and allows a step-up dosing that reduces adverse events, such as cytokine release syndrome, with promising tolerability. At the same time, it improves outcomes in the evolving landscape of FL management, even in post-CAR-T FL patients. Prognostic factors and targetable mechanisms of resistance need to be explored.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma. 免疫疗法治疗转移性和局部晚期胃食管腺癌的现状和前景。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1080/14712598.2024.2395921
Izuma Nakayama, Kohei Shitara
{"title":"The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma.","authors":"Izuma Nakayama, Kohei Shitara","doi":"10.1080/14712598.2024.2395921","DOIUrl":"10.1080/14712598.2024.2395921","url":null,"abstract":"<p><strong>Introduction: </strong>Immunochemotherapy with PD-1 blockade has been established as the current standard first-line therapy for patients with mGEA. Reviewing the history of clinical trials offers valuable insight into the evolution of immune oncology in mGEA, paving the way for future advancements in this field.</p><p><strong>Areas covered: </strong>This review summarizes the findings of previous clinical trials related to immunotherapy for patients with GEA in the metastatic and locally advanced setting. We also introduce ongoing clinical trials to address the current challenging issues in clinical practice.</p><p><strong>Expert opinion: </strong>In general, GEA exhibits intermediate immunogenic characteristics with heterogeneous expressions, and responders to anti-PD-(L)1 therapy are mostly enriched to patients with specific genomic profiles such as MSI-H, high PD-L1 expression, high TMB, and EBV-associated type. Co-administration with anti-angiogenic agents or simultaneous blockade of immune checkpoint molecules is being explored to offer benefit of immunotherapy for more patients. We hope that CLDN18.2 and upcoming targets like FGFR2b will complement the treatment niche of immunotherapy in the field of mGEA. Bispecific antibodies, antibody drug conjugates, CAR-T, and vaccine are anticipated to enhance efficacy and expand the scope of immunotherapy.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors. 克服 CAR-T 细胞疗法在抗原异质性实体瘤中的效率限制。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/14712598.2024.2399141
Astero Klampatsa
{"title":"Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors.","authors":"Astero Klampatsa","doi":"10.1080/14712598.2024.2399141","DOIUrl":"10.1080/14712598.2024.2399141","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信